Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Neratinib (Primary) ; Everolimus; Palbociclib; Trametinib
- Indications Solid tumours
- Focus Adverse reactions
- 31 Oct 2017 Planned End Date changed from 1 Apr 2023 to 1 Oct 2022.
- 31 Oct 2017 Planned primary completion date changed from 1 Apr 2023 to 1 Oct 2022.
- 31 Oct 2017 Status changed from not yet recruiting to recruiting.